MRK Stock Recent News

MRK LATEST HEADLINES

MRK Stock News Image - Zacks Investment Research

Merck (MRK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $1.62 per share a year ago.

Zacks Investment Research 2024 Feb 01
MRK Stock News Image - CNBC Television

CNBC's Mike Santoli reports on the company's quarterly earnings results.

CNBC Television 2024 Feb 01
MRK Stock News Image - Barrons

Merck posted a 3-cent a share loss on revenue of $14.6 billion in the fourth quarter. Analysts surveyed by FactSet had expected Merck to report an 11-cent loss on revenue of $14.5 billion.

Barrons 2024 Feb 01
MRK Stock News Image - Reuters

Merck & Co on Thursday reported better-than-expected fourth-quarter results on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine.

Reuters 2024 Feb 01
MRK Stock News Image - Market Watch

Merck & Co. Inc. on Thursday reported fourth-quarter earnings and sales that beat analysts' expectations, powered by strong growth in cancer and vaccine products.

Market Watch 2024 Feb 01
MRK Stock News Image - CNBC

Merck still posted a quarterly loss due to previously announced charges associated with its cancer drug collaboration deal with Daiichi Sankyo.

CNBC 2024 Feb 01
MRK Stock News Image - The Motley Fool

Merck is well on its way to replacing its most important growth driver. Fiverr will continue to benefit from the expanding gig economy.

The Motley Fool 2024 Jan 28
MRK Stock News Image - Zacks Investment Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Investment Research 2024 Jan 25
MRK Stock News Image - Zacks Investment Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.

Zacks Investment Research 2024 Jan 24
MRK Stock News Image - The Motley Fool

Merck plans to buy biotech Harpoon Therapeutics. Harpoon's platform is powerful, and it could produce many opportunities.

The Motley Fool 2024 Jan 23
10 of 50